The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Lupus - Lupus syndrome (see also Vd)
Publications
Overlapping drug-induced vasculitis, ANCA-associated vasculitis, and lupus nephritis caused by low-dose hydralazine.
International journal of rheumatic diseases. 2023;26(11):2272-2277
The Utility of Bronchoscopy in Hydralazine-Induced ANCA-Associated Vasculitis.
Case reports in pulmonology. 2023;2023:1461011
An intriguing case of anemia and renal failure.
Proceedings (Baylor University. Medical Center). 2019;32(1):78-79
Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2019;30(1):226-230
Arnaud L, Mertz P, Gavand PE, Martin T, Chasset F, Tebacher-Alt M, Lambert A, Muller C, Sibilia J, Lebrun-Vignes B, Salem JE
Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.
Annals of the rheumatic diseases. 2019;78(4):504-508
Hydralazine-induced lupus erythematosis.
Journal of clinical hypertension (Greenwich, Conn.). 2012;14(2):133-136
Hydralazine for essential hypertension.
The Cochrane database of systematic reviews. 2011;2011(11):CD004934
Drug-induced lupus erythematosus: incidence, management and prevention.
Drug safety. 2011;34(5):357-74
Do selected drugs increase the risk of lupus? A matched case-control study.
British journal of clinical pharmacology. 2010;70(4):588-96
Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis.
Modern rheumatology. 2009;19(3):338-47
Fulminating hydralazine-induced lupus pneumonitis.
Arthritis and rheumatism. 2006;55(3):501-6
Late systemic complications of hydralazine (apresoline) therapy.
Journal of the American Medical Association. 1955;157(11):894-9
Studies on the control of hypertension by hyphex. II. Toxic reactions and side effects.
Circulation. 1953;8(6):829-39
Hydralazine-induced lupus and vocal fold paralysis.
The Journal of laryngology and otology. 1998;112(9):875-7
Antigen specificity in hydralazine associated ANCA positive systemic vasculitis.
QJM : monthly journal of the Association of Physicians. 1995;88(11):775-83
Effect of acute cytomegalovirus infection on drug-induced SLE.
Postgraduate medical journal. 1994;70(828):738-40
Drug-induced lupus caused by very-low-dose hydralazine.
British journal of rheumatology. 1986;25(2):225
Laryngeal manifestations of drug induced lupus.
The Journal of rheumatology. 1987;14(2):375-7
Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus.
Clinical and experimental immunology. 1990;81(3):380-3
Hypocomplementemia in hydralazine-associated systemic lupus erythematosus.
The American journal of medicine. 1978;65(3):553-6